Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-2-propenoic Acid
2. 4-(1-imidazoylmethyl)cinnamic Acid
3. Oky 046
4. Oky-046
5. Ozagrel
6. Ozagrel, Monohydrochloride
7. Ozagrel, Monohydrochloride, (e)-isomer
8. Sodium Ozagrel
1. 130952-46-4
2. 189224-26-8
3. Cataclot
4. Xanbon
5. Sodium Ozagrel
6. Ozagrel (sodium)
7. Athrombone
8. Kadenin
9. Ozagrel Sodium [jan]
10. Ozagrel Sodium Salt [mi]
11. Sodium (e)-3-(4-((1h-imidazol-1-yl)methyl)phenyl)acrylate
12. Ozagrel Sodium [who-dd]
13. Sodium 3-(4-((1h-imidazol-1-yl)methyl)phenyl)acrylate
14. Kw-01
15. 4x5577n3et
16. 189224-26-8 (sodium)
17. 2-propenoic Acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, Sodium Salt, (2e)-
18. 2-propenoic Acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, Sodium Salt, (e)-
19. 2-propenoic Acid, 3-[4-(1h-imidazol-1-ylmethyl)phenyl]-, Sodium Salt (1:1)
20. 2-propenoic Acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, Sodium Salt (1:1), (2e)-
21. Sodium;(e)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate
22. Unii-4x5577n3et
23. Xanbons
24. Ozapen (tn)
25. Ozagrel Sodium (jp17)
26. Schembl3093220
27. Sodium,3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate
28. Hy-b0428a
29. Amy3367
30. Dtxsid50172327
31. Hms3887a15
32. Bcp12393
33. Ex-a5745
34. Akos015895382
35. Akos015967214
36. Akos025149474
37. Ccg-266963
38. Cs-3808
39. Ac-15516
40. As-12150
41. Gd95350000
42. D01684
43. A912378
44. Oky-046 Sodium;oky 046 Sodium;oky046 Sodium
45. Q27260625
46. Sodium(e)-3-(4-((1h-imidazol-1-yl)methyl)phenyl)acrylate
| Molecular Weight | 250.23 g/mol |
|---|---|
| Molecular Formula | C13H11N2NaO2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 250.07182188 g/mol |
| Monoisotopic Mass | 250.07182188 g/mol |
| Topological Polar Surface Area | 58 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 289 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Histamine Antagonists
Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Ozagrel Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ozagrel Sodium, including repackagers and relabelers. The FDA regulates Ozagrel Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ozagrel Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ozagrel Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ozagrel Sodium supplier is an individual or a company that provides Ozagrel Sodium active pharmaceutical ingredient (API) or Ozagrel Sodium finished formulations upon request. The Ozagrel Sodium suppliers may include Ozagrel Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Ozagrel Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ozagrel Sodium Drug Master File in Japan (Ozagrel Sodium JDMF) empowers Ozagrel Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ozagrel Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Ozagrel Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ozagrel Sodium suppliers with JDMF on PharmaCompass.
Ozagrel Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ozagrel Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ozagrel Sodium GMP manufacturer or Ozagrel Sodium GMP API supplier for your needs.
A Ozagrel Sodium CoA (Certificate of Analysis) is a formal document that attests to Ozagrel Sodium's compliance with Ozagrel Sodium specifications and serves as a tool for batch-level quality control.
Ozagrel Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Ozagrel Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ozagrel Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Ozagrel Sodium EP), Ozagrel Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ozagrel Sodium USP).
LOOKING FOR A SUPPLIER?
